NEWS

NEWS

Total 79

59
NeoImmuneTech to Present at Immuno-Oncology Summit Europe 2022
2022-05-19
58
NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase II Study of NT-I7 and Pembrolizumab in Recurrent Glioblastoma
2022-05-11
57
NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting
2022-04-28
56
NeoImmuneTech Demonstrates NT-I7’s Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022
2022-04-14
55
NeoImmuneTech to Celebrate First Year of Trading at KOSDAQ
2022-03-16
54
NeoImmuneTech to Present Two Posters at American Association for Cancer Research Annual Meeting
2022-03-10
53
NeoImmuneTech to Present at Upcoming Business Conferences
2022-02-09
52
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 checkpoint inhibitor in High-Risk Skin Cancers
2022-02-07
51
Preclinical Data on NT-I7 Published in Clinical Cancer Research
2022-01-24
50
NeoImmuneTech to Present at 2022 Biotech Showcase at J.P. Morgan Healthcare Conference
2022-01-05

1 2 3 4 5 >>>